Great to see a PR for ENTB and optimism that 2017 should be the year for canine and feline cancer therapies. IMO, I believe from years of prior testing they know that the therapy works in animals.
From 12/21/16 ENTB PR: The Company is currently working on codifying its plans and activities in a new website that should be up shortly so everyone can track its progress." Further stated Dr. Koos, "I believe 2017 should be a year we see great progress in bringing new small molecule therapies for animals within reach." .
Its been stated previously that they plan on funding Regen from a revenue stream from ENTB. Give that the speed to market is far greater for animal drugs 2017 is possible. Personally I would not be opposed to a buyout of ENTB to accomplish that revenue goal. Regen has worked with Eli Lilly on NR2F6 and Eli Lilly has a pet division(Elanco). Time will tell.
I would like to see further communication from Koos on ENTB similar to what Lander does for Regen. Lets hope.
News 
Market Data 
Discover 
